Albany, NY -- (SBWIRE) -- 02/11/2016 -- Transparency Market Research has created a new report on the pharmaceutical industry. The research report, titled "Autologous Stem Cell and Non-Stem Cell Based Therapies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023", pursues the key trends, drivers, and restraints that shape this market and provides suitable prognoses for the market's future.

As stated by the U.S. Food and Drugs Administration, autologous processes imply the infusion, transplantation, implantation, or other processes that involve the transfer of human cells into himself/herself. The global autologous stem cell and non-stem cell based therapies market includes procedures that are useful in the treatment of aplastic anemia, Hodgkin's lymphoma, non-Hodgkin lymphoma, multiple myeloma, and other bone marrow diseases. This treatment has also extended to other diseases such as diabetes, thalassemia, and Parkinson's disease.

Request a Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4001

Modern uses of autologous cell therapies involve the elimination of residual cancer cells after intense sessions of chemo, as well as helping in the regeneration of vital bone marrow after the chemo.

The use of autologous cell therapies is not without consequences, though. Medical complications may occur with the use of autologous cells, including cardiovascular complications, infertility, severe infections, vomiting, nausea, diarrhea, and hair loss.

The various application segments of the global autologous stem cell and non-stem cell based therapies market are cardiovascular diseases, cancer and tumors, autoimmune diseases, neurodegenerative disorders, and other infectious diseases.

One of the greater drivers of the global autologous stem cell and non-stem cell based therapies market in the near future is its expanding scope of use in the field of cosmetic surgery treatment. The use of autologous cell therapies in cosmetic surgery has been showing longer lasting results in comparison to traditional treatments. This segment is therefore receiving more attention, as it exhibits promising prospects.

The global autologous stem cell and non-stem cell based therapies market has consistently been dominated by North America, with Europe in tow. Both regions have shown stellar growth rates in this market owing to the growing demand in these regions for the use of minimal risk procedures for a wide array of dangerous and infectious illnesses. At the same time, the advantage that autologous cell therapy provides – of not needing an additional donor – makes it easier for the healthcare sector to create more scope for growth of this market.

The key players in the global autologous stem cell and non-stem cell based therapies market are Genzyme Corporation, Regeneus Ltd., NeoStem, Inc., BrainStorm Cell Therapeutics, Dendreon Corporation, Fibrocell Science, Inc., and Aastrom Biosciences. Most of these companies are developing autologous cell therapies for the treatment of chronic diseases.

Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/